MBX Biosciences first patient dosed in Phase 3 oPTimize trial
MBX Biosciences announced first patient dosed in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism.
Story updates
12:07:41 PM UTC
SquawkNews
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.